In A Nutshell Johns Hopkins researchers developed a blood test that catches 81% of stage IA lung cancers (the earliest, most ...
Cancer diagnoses traditionally require invasive or labor-intensive procedures such as tissue biopsies. Researchers at the Ludwig-Maximilians-Universität München (LMU) have now reported on a method ...
University of Queensland researchers who mapped cancer cell "neighborhoods" in the most common type of lung cancer have found ...
Researchers at Moffitt Cancer Center have developed a new tool to predict how cancer cells evolve. By focusing on chromosome ...
Lung cancer is the second-most common cancer and the leading cause of cancer death in the United States. Over 80% of lung cancers are non-small cell lung cancers, in which tumor cells are larger and ...
Artificial intelligence-powered spatial analysis of tumor microenvironment in non-small cell lung cancer patients who acquired resistance after EGFR tyrosine kinase inhibitors. This is an ASCO Meeting ...
Response and long-term survival in stage IV lung adenocarcinoma as predicted by serial 3-D explant analyses with molecular correlates: Tumor biology as evolutionary biology. This is an ASCO Meeting ...
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage cancer diagnostics including CyPath® Lung, the Company’s commercially available test for early-stage ...